Tuscan Holdings Corp (NASDAQ: THCB) To Merger With Microvast As Agenus Inc. (NASDAQ AGEN) Signs Licensing Deal With Bristol Myers Squibb (NYSE: BMY)

Tuscan Holdings Corp (NASDAQ: THCB)  has announced a scheduled special stockholder meeting to approve its proposed merger with Microvast Inc.  Microvast, a leading next-generation battery technologies provider for specialty and commercial vehicles.

Tuscan to vote on the proposed merger with Microvast

The meeting will take place on July 21, 2021, at 9:00 am ET, and the company has emailed stockholders who were on record as of June 21, 2021, the notice for the special meeting and associated proxy materials. The consummation of the business combination requires approval from 50% of holders of outstanding Tuscan Shares. Voting will be open to shareholders who held shares as of June 21, 2021. 

Shareholders who held shares as of the Record date should submit the vote immediately to ensure its represented during the meeting. Also, those stockholders whose shares are held through banks or brokerage firms are advised to instruct the broker or bank to vote. 

Agenus closes licensing deal for AGN1777 with Bristol Myers. 

Agenus Inc. has announced closing a licensing deal with Bristol Myers Squibb Co. (NYSE: BMY). According to the terms of the agreement, Bristol Myers will study an Agenus’s immune-oncology drug as a non-small cell lung cancer treatment. In addition, Bristol Myers will have an exclusive license to AGEN1777. AGEN1777 is an Fc-enhanced antibody the company is developing in late preclinical studies that inhibit receptors expressed by NK and T cells to enhance anti-tumor activity.  

Following the agreement’s closing, Agenus will receive an upfront payment of $200 million with around $1.3 billion in future development, commercial, and regulatory milestone payments. In addition, Agenus retains the option to conduct clinical studies and combination studies with other assets and co-promoting AGEN1777 in the US. 

Leave a Comment

Your email address will not be published.